Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 3414

Drug Profile

MEDI 3414

Alternative Names: Live attenuated nasal spray vaccine for H1N1 - MedImmune; MEDI-3414; Monovalent live attenuated pandemic influenza vaccine - MedImmune; Pandemic flu vaccine - MedImmune; Pandemic H1N1 influenza vaccine - MedImmune; Pandemic vaccines - MedImmune/NIAID

Latest Information Update: 16 Feb 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune; National Institute of Allergy and Infectious Diseases
  • Developer MedImmune
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 15 Sep 2009 Registered for prevention of Influenza-A virus H1N1 subtype in USA (Intranasal)
  • 15 Sep 2009 Interim immunogenicity & adverse events data from clinical trials in volunteers released by the US FDA
  • 19 Feb 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top